The continuous emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) variants poses challenges to the effectiveness of neutralizing antibodies. Rational design …

Background Neutralizing antibodies are approved drugs to treat coronavirus disease-2019
(COVID-19) patients, yet mutations in severe acute respiratory syndrome coronavirus (SARS …

The global pandemic of COVID-19 caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) has resulted in widespread social and economic disruption …

Multiple new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
have constantly emerged, as the delta and omicron variants, which have developed …

Monoclonal antibodies (MAbs) targeting the Spike glycoprotein of SARS-CoV-2 is a key
strategy to prevent severe COVID-19. Here, the efficacy of two monoclonal antibody …

SARS-CoV-2 continues to be a public health burden, driven in-part by its continued
antigenic diversification and resulting emergence of new variants. While increasing herd …

As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants continue to
emerge and spread around the world, antibodies and vaccines to confer broad and potent …

The constant mutation of SARS-CoV-2 has led to the emergence of new variants, which call
for urgent effective therapeutic interventions. The trimeric spike (S) protein of SARS-CoV-2 is …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has precipitated multiple
variants resistant to therapeutic antibodies. In this study, 12 high-affinity antibodies were …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread rapidly over the
world and claimed million lives. The virus evolves constantly, and a swarm of mutants is a …